Coloma Jason V 4

What Happened

• Jason V. Coloma, CEO of Maze Therapeutics (MAZE), reported open-market sales totaling 27,858 shares for aggregate proceeds of roughly $725,495. The filings show: 1,953 shares sold on 2026-06-22 at $26.00 ($50,781); 2,040 shares sold on 2026-06-22 at $26.00 ($53,040); and 23,865 shares sold on 2026-06-23 at a reported weighted-average price of $26.05 ($621,674). These were sales (not purchases).

Key Details

• Transaction dates and prices:
  • 2026-06-22: 1,953 shares @ $26.00 = $50,781
  • 2026-06-22: 2,040 shares @ $26.00 = $53,040
  • 2026-06-23: 23,865 shares @ reported weighted avg $26.05 = $621,674
• Total proceeds: approximately $725,495.
• Reporting/filing: Form 4 filed 2026-06-24; transactions occurred 2026-06-22 and 06-23 — appears to be within the standard two-business-day Form 4 filing window.
• Footnotes of note:
  • F1: Sales were effected under a Rule 10b5-1 trading plan adopted Feb 6, 2026 (pre-arranged trading plan).
  • F2 / F5: Reported prices are weighted averages; the filing notes sales occurred across multiple transactions at per-share price ranges (e.g., $26.00–$26.025 and $26.00–$26.185) and the filer can provide a breakdown on request.
  • F3 / F4: Some securities are held directly by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Mr. Coloma and his spouse serve as co-trustees.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

• The sales were made under a pre-established 10b5-1 plan, which generally allows insiders to sell pre-scheduled amounts regardless of any subsequent material nonpublic information. Sales under such plans are common and do not necessarily indicate a change in the insider's view of the company.
• As these are disposals (S), they are less informative than purchases about insider sentiment; retail investors may note the size and timing but should not infer motive from the sale alone.